F-18 16 Alpha-Fluoroestradiol

also known as 18F-FES · [18F]fluoroestradiol · FES · 16α-(18)F-fluoro-17β-estradiol · [F-18] FES · Fluoroestradiol (18F) · 16-alpha-18F-fluoro-17-beta-estradiol · Fluorine-18 (18F) Fluoroestradiol

Diagnostic / imaging agent

Trials 19 · a red edge is where a trial was stopped

today NCT05982496 · Ph 2 NCT06260033 · Ph 2 NCT05916196 · Ph 2 NCT05659797 · Ph 0 NCT05960201 · Ph 2 NCT04347135 · Ph 1/2 NCT05486182 · Ph 4 NCT04692103 · Ph 2 NCT04252859 · Ph 2 NCT04382911 · Ph 2 NCT03703492 · Ph 2 NCT03544762 · Ph 3 NCT02398773 · Ph 2 NCT02409316 · Ph 2 NCT03507088 · not/applicable NCT02374931 · Ph 0 NCT01986569 · Ph 3 NCT01627704 · not/applicable NCT02149173 · not/applicable

20112012201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT05659797	Oct 2023 → Jan 2028 expected	breast cancer	Abramson Cancer Center at Penn Medicine	Recruiting	No outcome recorded
Phase 0	NCT02374931	Apr 2015 → Jul 2017	classic familial adenomatous polyposis, desmoid tumor	Vanderbilt-Ingram Cancer Center	Terminated	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT04347135	Oct 2022 → Apr 2024	endometriosis	Annie (Annie) T. Packard	Withdrawn	No outcome recorded
Phase 210 trials
Phase 2	NCT05982496	Jun 2026 → Jun 2029 expected	female breast carcinoma, invasive lobular breast carcinoma, luminal A breast carcinoma, lymph node disorder	Vita-Salute San Raffaele University	Recruiting	No outcome recorded
Phase 2	NCT06260033	Jul 2024 → Oct 2026 expected	estrogen-receptor positive breast cancer, female breast carcinoma	City of Hope Medical Center	Recruiting	No outcome recorded
Phase 2	NCT05916196	Apr 2024 → Aug 2027 expected	uterine cancer	Abramson Cancer Center at Penn Medicine	Recruiting	No outcome recorded
Phase 2	NCT05960201	Aug 2023 → Aug 2024	invasive lobular breast carcinoma	Asan Medical Center	Completed	No outcome recorded
Phase 2	NCT04692103	Jul → Oct 2021 overdue	estrogen-receptor positive breast cancer	University of Washington	Active not recruiting	No outcome recorded
Phase 2	NCT04252859	Dec 2020 → Dec 2024	invasive lobular breast carcinoma	University of Utah	Terminated	No outcome recorded
Phase 2	NCT04382911	Aug 2020 → Jul 2022	endometriosis	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 2	NCT03703492	Jan 2019 → Jan 2024	ductal breast carcinoma in situ	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 2	NCT02398773	May 2016 → Dec 2026 expected	Her2-receptor negative breast cancer, progesterone-receptor negative breast cancer, progesterone-receptor positive breast cancer	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT02409316	Oct 2015 → Aug 2025	estrogen-receptor positive breast cancer	University of Pennsylvania	Terminated	No outcome recorded
Phase 32 trials
Phase 3	NCT03544762	Sep 2017 → Dec 2020	breast cancer	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 3	NCT01986569	Nov 2013 → Nov 2016	female breast carcinoma	Asan Medical Center	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT05486182	Feb 2022 → Apr 2025 overdue	breast cancer	GE Healthcare	Active not recruiting	No outcome recorded
Phase not applicable3 trials
—	NCT03507088	Sep 2015 → Jul 2018	breast cancer	Zhimin Shao	Completed	No outcome recorded
—	NCT01627704	Jun 2012 → Jan 2015	breast cancer	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
—	NCT02149173	Sep 2010 → Dec 2018	estrogen-receptor positive breast cancer	University of Washington	Terminated	No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 20 sources stand behind the page.

Field	Value	Cited text
Known as	F-18 16 Alpha-Fluoroestradiol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04692103 ↗ 4 NCT02398773 ↗ NCT06260033 ↗ NCT02374931 ↗ NCT02149173 ↗
Known as	16-alpha-18F-fluoro-17-beta-estradiol	“16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam” NCT05982496 ↗
Known as	16α-(18)F-fluoro-17β-estradiol	“16α-\[18F\]fluoro-17β-estradiol (\[18F\]FES) is currently the only ER-targeted PET agent validated in previous clinical trials.” NCT03544762 ↗ 1 “Pilot Study Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI” NCT04347135 ↗
Known as	18F-FES	“16α-\[18F\]fluoro-17β-estradiol (\[18F\]FES) is currently the only ER-targeted PET agent validated in previous clinical trials.” NCT03544762 ↗ 5 “18F-fluoroestradiol (18F-FES) PET/CT” PMID 40813238 ↗ Oct 2025 NCT02409316 ↗ NCT05659797 ↗ NCT03703492 ↗ NCT03544762 ↗
Known as	[18F]fluoroestradiol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05960201 ↗ 5 NCT01986569 ↗ NCT05486182 ↗ NCT04252859 ↗ NCT04382911 ↗ NCT05916196 ↗
Known as	[F-18] FES	“Pilot Study Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI” NCT04347135 ↗ 1 NCT04347135 ↗
Known as	FES	“The primary objective is to evaluate the sensitivity and specificity of 18F-fluoroestradiol (FES) PET/MRI for evaluating endometriosis.” NCT04382911 ↗ 4 “[18F]Fluoroestradiol (FES) PET/CT” NCT04252859 ↗ “[18F]fluoroestradiol (FES)” NCT05960201 ↗ “[18F]fluoroestradiol (FES)” NCT01986569 ↗ NCT05982496 ↗
Known as	Fluorine-18 (18F) Fluoroestradiol	“Fluorine-18 (18F) Fluoroestradiol” NCT04252859 ↗
Known as	Fluoroestradiol (18F)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03507088 ↗ 1 NCT01627704 ↗
Modality	Diagnostic / imaging agent	“evaluate diagnostic performance of FES PET/CT” NCT01627704 ↗
Route	Intravenous	“one single IV injection” NCT01627704 ↗